Related Experiment Videos
Serotonergic modulation and irritable bowel syndrome.
1Pharmagene plc, 2 Orchard Road, Royston, Herts., SG8 5HD, UK. richard.borman@pharmagene.com
Expert Opinion on Emerging Drugs
|July 2, 2005
Summary
Irritable bowel syndrome (IBS) is a common gastrointestinal disorder. Serotonin receptor targeted therapies show promise for IBS symptom relief, but further research is needed for validation.
Area of Science:
- Gastroenterology
- Pharmacology
- Neurogastroenterology
Background:
- Irritable bowel syndrome (IBS) is a prevalent gastrointestinal disorder affecting women more than men, characterized by abdominal pain, cramping, and altered bowel habits.
- The exact cause of IBS is unknown, but potential factors include gut-brain axis dysfunction, motility issues, visceral hypersensitivity, and inflammation.
- Current IBS treatments are limited, but targeting serotonin (5-HT) receptors shows potential for symptom management.
Purpose of the Study:
- To explore the role of serotonin (5-HT) and its receptors in the pathophysiology and treatment of Irritable Bowel Syndrome (IBS).
- To review the efficacy and limitations of current and emerging serotonergic drugs for IBS management.
Main Methods:
- Review of existing literature on IBS, serotonin's role in gastrointestinal function, and clinical studies of serotonergic drugs.
- Analysis of the mechanisms of action for 5-HT receptor antagonists and agonists in IBS.
- Evaluation of patient responses and safety profiles of specific IBS medications like alosetron and tegaserod.
Main Results:
- Serotonin (5-HT) influences diverse gastrointestinal functions, and altered 5-HT metabolism (elevated 5-HIAA) is observed in IBS patients.
- 5-HT3 antagonist alosetron showed efficacy only in female IBS patients with diarrhea but was withdrawn due to safety concerns.
- 5-HT4 agonist tegaserod demonstrates promise for constipation-predominant IBS and is under review.
Conclusions:
- Serotonergic modulation offers a potential therapeutic avenue for IBS, particularly for specific patient subsets and symptoms.
- Further research is essential to fully understand the mechanisms, identify patient responders, and ensure the safety of serotonergic treatments for IBS.
- The differential efficacy and side effect profiles of serotonergic drugs highlight the complexity of IBS and the need for personalized treatment approaches.